stockportfolio.pro
Stocks / LLY vs NVS
LLY vs NVS
Eli Lilly and Company and Novartis AG side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Eli Lilly and Company (LLY) | Novartis AG (NVS) | |
|---|---|---|
| Market cap | $1.01T | $290.6B |
| Revenue (latest FY) | $65.18B | $56.67B |
| Net income (latest FY) | $20.64B | $13.98B |
| Revenue growth (5y CAGR) | 21.6% | 9.3% |
| Net margin | 31.7% | 24.7% |
| Return on equity | 77.8% | 30.3% |
| P/E ratio | 40.3 | 21.8 |
| Dividend yield | 0.6% | 3.2% |
| Profitable years (of last 10) | 9 | 4 |
| Positive free cash flow | — | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open LLY — free Open NVS — freeFrequently asked questions
Which is bigger, LLY or NVS?
Eli Lilly and Company is larger by market capitalization — $1.01T versus $290.6B.
Which grows faster, LLY or NVS?
Over the last five fiscal years, Eli Lilly and Company grew revenue faster — 21.6%/yr versus 9.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.